van der Wall SJ, Lip GYH, Teutsch C, Kalejs O, Lyrer P, Hall C, Dubner SJ, Diener HC, Halperin JL, Ma CS, Rothman KJ, Zint K, Zhai D, Huisman MV, GLORIA-AF Investigators. Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study. Eur J Intern Med. 2021 Sep;91:75-80. doi: 10.1016/j.ejim.2021.05.020
Lin HM, Davis KL, Kaye JA, Luptakova K, Nagar SP, Mohty M. Real-world treatment patterns, outcomes, and healthcare resource utilization in relapsed or refractory multiple myeloma: evidence from a medical record review in France. Adv Hematol. 2019 Jan 29;2019(4625787). doi: 10.1155/2019/4625787
Davis KL, Cote I, Kaye JA, Mendelson E, Gao H, Perez Ronco J. Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol. 2015 Oct;2015(2015):848473. doi: 10.1155/2015/848473
Mauskopf JA, Candrilli SD, Chevrou-Severac H, Ochoa JB. Immunonutrition for patients undergoing elective surgery for gastrointestinal cancer: impact on hospital costs. World J Surg Oncol. 2012 Jul 1;10:136.